Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective/background: Comorbid insomnia with obstructive sleep apnea (COMISA) is associated with worse daytime function and more medical/psychiatric comorbidities vs either condition alone. COMISA may negatively impact sleep duration and reduce rapid eye movement (REM) sleep, thereby impairing cognition. These post-hoc analyses evaluated the effect of lemborexant (LEM), a dual-orexin-receptor antagonist approved for adults with insomnia, on sleep architecture in participants with COMISA.
Patients/methods: E2006-G000-304 was a phase 3, one-month polysomnography trial in adults aged ≥55 years with insomnia receiving LEM 5 mg (LEM5) or 10 mg (LEM10), placebo (PBO), or zolpidem-tartrate-extended-release 6.25 mg (ZOL). Sleep architecture was determined from 2 nights during placebo run-in (baseline), nights 1 and 2 (NT1/2), and nights 29 and 30 (NT29/30) of treatment.
Results: In the Full Analysis Set, 40.8 % (410/1006) had mild obstructive sleep apnea (OSA; apnea-hypopnea-index ≥5 and <15 events/hour of sleep). Mean change from baseline (CFB) in total sleep time (TST) was significantly greater at NT1/2 and NT29/30 with LEM5 and LEM10 vs ZOL (NT1/2, LEM5, P ≥ 0.05; LEM10, P < 0.0001; NT29/30, both P < 0.0001) and PBO (NT1/2 and NT29/30, all P < 0.0001). REM sleep and REM latency CFB were significantly greater (P < 0.0001 and P < 0.01, respectively) for LEM5 and LEM10 vs PBO/ZOL at NT1/2 and NT29/30.
Conclusions: LEM significantly increased TST in participants with insomnia and mild OSA. Importantly, REM sleep, associated with cognitive performance, increased. These data support the use of LEM in patients with insomnia and mild OSA.
Gov Registration: NCT02783729.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.sleep.2024.12.023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Time-dependent cortical responses to siesta disruption in male mice.
Front Neurosci
August 2025
Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Introduction: Siestas, or daytime naps, play a critical role in relieving sleep pressure and maintaining physiological balance. However, the effects of siesta disruption remain largely unexplored.
Methods: In this study, we disrupted the natural siesta period (ZT20-23) through daily bedding changes for 2 weeks and examined its effects on overall stress levels, sleep architecture, behavior, and transcriptional responses in the frontal cortex.
Light does not phase shift the circadian clock of subcutaneous adipose tissue in vitro.
NPJ Biol Timing Sleep
September 2025
Healthy Living Spaces Lab, Institute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany.
The retinal photopigment melanopsin is also expressed in subcutaneous white adipose tissue (scWAT). Through melanopsin, light can modulate scWAT metabolism, but its impact on circadian phase is unclear. In vitro exposure of murine scWAT to bright light at different times over 24 h did not elicit phase shifts, unlike the response to corticosterone.
View Article and Find Full Text PDFHomeostatic forces underlying the daily pattern of sleep propensity.
Sleep Adv
July 2025
Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118, United States.
The mismatch between rising sleep need and the fluctuating ability to fall asleep underlies insomnia-the most common sleep disorder-yet remains poorly understood. While sleep need increases steadily with time awake, sleep propensity-the likelihood of transitioning from wake to sleep-follows a bimodal pattern, peaking in the mid-afternoon, dipping in the evening, and rising again near bedtime. Building on our previously developed wave model of sleep dynamics, we extend this homeostatic framework to the waking period and show that it predicts the observed bimodal sleep propensity curve.
View Article and Find Full Text PDFTransdermal, Infusion, and Surgical Therapies and Effect on Sleep Dysfunction in Parkinson's Disease.
Sleep Med Clin
September 2025
Parkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, United Kingdom; King's College Hospital, London, Dubai, UAE; Institute of Psychiatry, Psychology and Neuroscience, King's College, Dementech Clinical Neuroscience Centre London, United Kingdom. Electronic
Sleep dysfunction is dominant in patients on oral dopamine replacement therapies as nighttime therapy is suboptimal and often not attempted. Non oral infusion-based Parkinson's disease (PD) therapies, transdermal therapies, as well as deep brain stimulation (DBS) of the subthalamic nucleus (STN) bridge this gap and provide nighttime cover in most cases in PD. DBS of the STN also show significant improvement in PD sleep scale scores and improvement in sleep quality.
View Article and Find Full Text PDFPrevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy.
JAMA Cardiol
September 2025
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Importance: Sleep disordered breathing (SDB) is a well-established contributor to cardiovascular morbidity, mediated by intermittent hypoxemia, autonomic dysregulation, and endothelial dysfunction. Patients with hypertrophic cardiomyopathy (HCM) may be especially at risk for SDB, but the clinical impact of SDB in this population remains unclear.
Objective: To define the prevalence and subtypes of SDB in HCM and examine their association with echocardiographic parameters and cardiac biomarker expression.